Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1159/000444926 http://scihub22266oqcxt.onion/10.1159/000444926 C5292033!5292033!26954668     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nephron 2016 ; 134 (1): 37-42 Nephropedia Template TP {{tp|p=26954668|t=2016. Targeting Glycosphingolipid Metabolism to Treat Kidney Disease |pdf=|usr=}}{{26954668}} gab.com Text Targeting Glycosphingolipid Metabolism to Treat Kidney Disease JO: Nephron http://www.kidney.de/pget.php?&tw=1&pmid=26954668 #FOAvip The enhanced expression of glucosylceramide based glycosphingolipids is a hallmark of many forms of renal disease including diabetic nephropathy, polycystic kidney disease, and renal cell carcinoma. A common feature of each of these renal disorders is the preference metabolism of via aerobic glycolysis. While aerobic glycolysis is an inefficient way to generate ATP, aerobic glycolysis promotes the formation of substrates important for the production of biomass, including lipids, amino acids, and nucleotides through the pentose phosphate pathway. Two products that are essential for the synthesis of glucosylceramide and more complex glycosphingolipids are generated through the pentose phosphate pathway. These products are reducing equivalents in the form of NADPH and UDP-glucose. In experimental models of each of these disorders, inhibition of glucosylceramide synthase with eliglustat or related analogues reverses the disease phenotype suggesting that blocking glycosphingolipid synthesis should be explored as a potential treatment strategy. Twit Text FOAVip Targeting Glycosphingolipid Metabolism to Treat Kidney Disease ????Nephron http://www.kidney.de/pget.php?&tw=1&pmid=26954668 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26954668 #FOAvip English Wikipedia <ref>{{Cite pmid|26954668}}</ref> Targeting Glycosphingolipid Metabolism to Treat Kidney Disease #MMPMID26954668 Shayman JA Nephron 2016[]; 134 (1): 37-42 PMID26954668show ga The enhanced expression of glucosylceramide based glycosphingolipids is a hallmark of many forms of renal disease including diabetic nephropathy, polycystic kidney disease, and renal cell carcinoma. A common feature of each of these renal disorders is the preference metabolism of via aerobic glycolysis. While aerobic glycolysis is an inefficient way to generate ATP, aerobic glycolysis promotes the formation of substrates important for the production of biomass, including lipids, amino acids, and nucleotides through the pentose phosphate pathway. Two products that are essential for the synthesis of glucosylceramide and more complex glycosphingolipids are generated through the pentose phosphate pathway. These products are reducing equivalents in the form of NADPH and UDP-glucose. In experimental models of each of these disorders, inhibition of glucosylceramide synthase with eliglustat or related analogues reverses the disease phenotype suggesting that blocking glycosphingolipid synthesis should be explored as a potential treatment strategy. äTargeting Glycosphingolipid Metabolism to Treat Kidney Disease (epmc).pdf DeepDyve Pubget Overpricing